Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae

The Journal of Antimicrobial Chemotherapy
C E CooperA R White

Abstract

Concentrations of amoxycillin/clavulanic acid achievable in the respiratory tract following oral dosage were assessed for in-vitro activity against beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae. In agar-dilution studies, 8 mg amoxycillin/l was required to inhibit 45 strains of beta-lactamase-producing B. catarrhalis, whereas all the strains were inhibited by 0.5 mg amoxycillin/l in the presence of 0.01 mg clavulanic acid/l. Similarly, 0.1 mg amoxycillin plus 0.05 mg clavulanic acid/l were bactericidal against beta-lactamase-producing strain of B. catarrhalis and prevented regrowth within 24 h. In tests against 43 beta-lactamase-producing strains of H. influenzae, concentrations of up to 128 mg amoxycillin/l were required for inhibition, whereas 32 strains (75%) were fully sensitive to amoxycillin (MIC 0.5 mg/l) in the presence of 0.12 mg clavulanic acid/l. These concentrations of amoxycillin/clavulanic acid were also bactericidal for a beta-lactamase-producing strain of H. influenzae. The study therefore showed that amoxycillin/clavulanic acid, at concentrations similar to those likely to be achieved in the respiratory tract following oral dosage, was bactericidal in vitro for beta-lacta...Continue Reading

Citations

Oct 1, 1993·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·P L Housden, M F Sullivan
Aug 26, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K McGregorT V Riley
Mar 1, 1994·International Journal of Antimicrobial Agents·W M Todd
Jan 5, 2002·Current Opinion in Pharmacology·L A MillerD J Payne
Oct 20, 2005·Clinical Pharmacokinetics·Amparo Sánchez Navarro
Jul 23, 2014·BMC Pharmacology & Toxicology·Michiel HaesekerAnnelies Verbon
Nov 7, 2007·International Journal of Antimicrobial Agents·Richard Bax
May 21, 2003·Journal of Veterinary Pharmacology and Therapeutics·T B VreeE Van Duuren
Jun 1, 1997·Journal of Chemotherapy·P BallG Rolinson
Feb 15, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·V MurbachF Jehl
Apr 26, 2017·Antimicrobial Agents and Chemotherapy·Alejandro HobermanNader Shaikh
Jul 26, 2019·Expert Review of Anti-infective Therapy·Marguerite L Monogue, David P Nicolau
Feb 5, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M R Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Related Papers

Biopharmaceutics & Drug Disposition
G D AllenB E Davies
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
K V RolstonG P Bodey
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
F Schumacher-PerdreauG Peters
© 2021 Meta ULC. All rights reserved